{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/06/03/3305943/8790/en/TG-Therapeutics-Announces-Positive-Results-from-Phase-1-Trial-Evaluating-Subcutaneous-BRIUMVI-ublituximab-xiiy.html", "message": "News view counter 777102 successfully enlarged"}